Table 2.

Summary of AEs

AE category	Oleclumab 1500 mg (n = 3)	Oleclumab 3000 mg (n = 3)	Total (N = 6)
Any AE	3 (100.0)	3 (100.0)	6 (100.0)
Any AE related to treatment	3 (100.0)	2 (66.7)	5 (83.3)
Any AE of CTCAE ≥ Grade 3	0	1 (33.3)	1 (16.7)
Any AE of CTCAE ≥ Grade 3, related to treatment	0	0	0
Any AE with an outcome of death	0	0	0
Any AE with an outcome of death, related to treatment	0	0	0
System Organ Class/Preferred Term
Patients with AE of CTCAE Grade ≥ 3	0	1 (33.3)	1 (16.7)
Investigations	0	1 (33.3)	1 (16.7)
Neutrophil count decreased	0	1 (33.3)	1 (16.7)

All data are presented as n (%)

AE adverse event; CTCAE Common Terminology Criteria for Adverse Events